DelveInsight’s “Ascites Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.
Key Takeaways from the Ascites Market Report
- In 2020, the total cases of Ascites due to cirrhosis in the 7MM were ~240,700. Malignant Ascites cases are calculated from ovarian cancer, stomach cancer, breast cancer, and colorectal cancer. In 2020, the number of cases of Ascites from these cancers was ~8,500; ~3,500; ~12,650; and ~10,300, respectively, in the US.
- The increase in Ascites Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
- As per DelveInsight analysis, the Ascites Market is anticipated to witness growth at a considerable CAGR.
- The leading Ascites Companies working in the market include Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others.
- Promising Ascites Therapies in the various stages of development include catumaxomab, aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), M701, Paracentesis, Recombinant Human Serum Albumin, and others.
- February 2024:- Wuhan YZY Biopharma Co., Ltd. announced a study of Phase 2 clinical trials for M701 and paracentesis. The phase II study is a controlled, open-label trial designed to assess the effectiveness and safety of M701 intra-peritoneal infusion for controlling malignant ascites in patients with gastrointestinal and ovarian cancer who are also receiving systemic therapy.
Discover which therapies are expected to grab the Ascites Market Share @ Ascites Market Outlook
Ascites Overview
Ascites is a medical condition characterized by the accumulation of fluid in the abdomen. This fluid buildup occurs in the space between the lining of the abdomen and the organs. It’s commonly associated with liver disease, particularly cirrhosis, but can also be caused by other conditions such as heart failure, cancer, or infection. Ascites can lead to abdominal swelling, discomfort, and difficulty breathing. Treatment typically involves addressing the underlying cause, reducing fluid intake, medications to remove excess fluid, and sometimes procedures to drain the fluid.
Ascites Epidemiology Insights
The epidemiology section of Ascites offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving Ascites Epidemiology trends @ Ascites Epidemiological Insights
Ascites Emerging Drugs
- BIV201: BioVie
- OCE-205: Ocelot Bio
Ascites Drugs Market
The Ascites Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Ascites signaling in Ascites are likely to uncover new therapeutic targets and further expand treatment options for patients.
Ascites Treatment Market Landscape
The Ascites treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Ascites has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
To learn more about Ascites treatment guidelines, visit @ Ascites Treatment Market Landscape
Ascites Market Outlook
The report’s outlook on the Ascites market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Ascites therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Ascites drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Ascites market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.
Ascites Drugs Uptake
The drug chapter of the Ascites report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Ascites.
Major Ascites Companies
Several Ascites Companies working in the market include Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others.
Learn more about the FDA-approved drugs for Ascites @ Drugs for Ascites Treatment
Scope of the Ascites Market Report
- Coverage- 7MM
- Ascites Companies- Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others.
- Ascites Therapies- catumaxomab, aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), M701, Paracentesis, Recombinant Human Serum Albumin, and others.
- Ascites Market Dynamics: Ascites Market Drivers and Barriers
- Ascites Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Ascites Drugs in development @ Ascites Clinical Trials Assessment
Table of Content
1. Key Insights
2. Executive Summary of Ascites
3. Competitive Intelligence Analysis for Ascites
4. Ascites: Market Overview at a Glance
5. Ascites: Disease Background and Overview
6. Patient Journey
7. Ascites Epidemiology and Patient Population
8. Ascites Treatment Algorithm, Current Treatment, and Medical Practices
9. Ascites Unmet Needs
10. Key Endpoints of Ascites Treatment
11. Ascites Marketed Products
12. Ascites Emerging Therapies
13. Ascites: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Ascites Market Outlook
16. Ascites Market Access and Reimbursement Overview
17. Ascites KOL Views
18. Ascites Market Drivers
19. Ascites Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/